Biotricity® Partners with Verizon to Develop EMS Solutions
14 Juillet 2020 - 2:00PM
Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer
healthcare technology company announced a strategic partnership
with Verizon (NYSE: VZ) to develop EMS solutions for First
Responders by integrating its Bioflux solution. Bioflux is a
high-precision, single-unit mobile cardiac telemetry (MCT) device
that provides real-time monitoring and transmission of patients'
ECG information. Integrating the Bioflux solution into Verizon's
EMS platform realizes an unmet need for First Responders, enabling
them to access critical, potentially life-saving data in real-time
and respond immediately in a crisis.
"We at Biotricity are committed to developing innovative
technology that provides healthcare workers and medical
professionals the vital patient data they need. Collaboration with
Verizon offers an exciting avenue for our team of experts to
deliver frontline workers a device that provides remote patient
diagnostics in real-time and potentially saves lives," said Spencer
LaDow, VP of Research & Development.
First Responders require connectivity and specialized equipment
to enable immediate response in a crisis. Biotricity’s device
provides continuous connectivity, real-time monitoring and
diagnostic reporting that will be integrated into Verizon’s current
EMS platform, fulfilling an unmet need. Partnering with Verizon
allows the company to fill this gap and access a new market while
adding a revenue stream. Once integrated, Verizon will use its
ecosystem and resources to bring the solution to market.
"Our technology is an obvious fit for a variety of markets, and
it is a privilege to see it applied in vital health care areas such
as First Responders. As a growing company, we have focused on the
remote patient monitoring market but are aware of the potential in
other markets for our solutions. Partnerships like this enable us
to expand our opportunities, creating new revenue streams, while
focusing on our core market," said Dr. Al-Siddiq, CEO of
Biotricity.
To learn more about this partnership, read Verizon’s Press
Release here.
Join our newsletter at: https://www.biotricity.com/contact-us/
or follow on:
Twitter: @biotricity_incFacebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
About Biotricity Inc.
Biotricity is a modern medical technology company focused on
delivering innovative, remote biometric monitoring solutions to the
medical and consumer markets, including diagnostic and
post-diagnostic solutions for chronic conditions and lifestyle
improvement. Biotricity’s R&D continues to focus on the
preventative healthcare market, with a vision of putting health
management into the hands of the individual. The company aims to
support the self-management of critical and chronic conditions with
the use of innovative solutions to ease the growing burden on the
healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements, which involve assumptions and describe
our future plans, strategies, and expectations, are generally
identifiable by use of the words “may,” “should,” “would,” “will,”
“could,” “scheduled,” “expect,” “anticipate,” “estimate,”
“believe,” “intend,” “seek,” “project,” or “goal” or the negative
of these words or other variations on these words or comparable
terminology. Forward-looking statements may include, without
limitation, statements regarding (i) the plans, objectives and
goals of management for future operations, including plans,
objectives or goals relating to the design, development and
commercialization of Bioflux or any of the Company’s other proposed
products or services, (ii) a projection of income (including
income/loss), earnings (including earnings/loss) per share, capital
expenditures, dividends, capital structure or other financial
items, (iii) the Company's future financial performance, (iv) the
regulatory regime in which the Company operates or intends to
operate and (v) the assumptions underlying or relating to any
statement described in points (i), (ii), (iii) or (iv) above. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances and may not be
realized because they are based upon the Company's current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
additional financing, the significant length of time and resources
associated with the development of its products and related
insufficient cash flows and resulting illiquidity, the Company's
inability to expand the Company's business, significant government
regulation of medical devices and the healthcare industry, lack of
product diversification, existing or increased competition, results
of arbitration and litigation, stock volatility and illiquidity,
and the Company's failure to implement the Company's business plans
or strategies. These and other factors are identified and described
in more detail in the Company's filings with the SEC. The Company
assumes no obligation to update any forward-looking statements in
order to reflect any event or circumstance that may arise after the
date of this release.
Media ContactsMcCoin & Smith Communications
Inc.Chris McCoin,Chris@mccoinsmith.com, 508-429-5988Richard
Smith,rick@mccoinsmith.com, 978-433-3304
Investor Relations:Biotricity
Inc.1-800-590-4155investors@biotricity.com
Verizon Communications (NYSE:VZ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Verizon Communications (NYSE:VZ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024